Antiarrhythmic drugs of class Ic in cardiology practice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatment of cardiac arrhythmias has consistently attracted the interest of researchers and practicing physicians. Class Ic antiarrhythmic drugs (AADs) have been the most discussed in recent decades due to conflicting research results. The objective of this review is to analyze the efficacy and safety of class Ic AADs available in the Russian Federation: lappaconitine hydrobromide, prolonged-release lappaconitine hydrobromide, propafenone, flecainide, and diethylaminopropionylethoxycarbonylaminophenothiazine. The pharmacological features (pharmacokinetics, pharmacodynamics), electrophysiological effects of class Ic AADs, and data on their efficacy in supraventricular and ventricular cardiac arrhythmias, which served as the basis for clinical recommendations, are presented. The safety, adverse events, limitations, and contraindications for the use of class Ic AADs, as well as the possibilities of individualizing therapy when using them, are discussed.

Full Text

Restricted Access

About the authors

S. G. Kanorsky

Kuban State Medical University

Author for correspondence.
Email: kanorskysg@mail.ru
ORCID iD: 0000-0003-1510-9204
SPIN-code: 7635-5330

MD, Professor

Russian Federation, Krasnodar

Yu. V. Shubik

Saint Petersburg State University

Email: kanorskysg@mail.ru
ORCID iD: 0000-0002-8736-1575
SPIN-code: 6541-4328

MD, Professor

Russian Federation, Saint Petersburg

References

  1. Slaven S., Garg L., Sabzwari R. et al. Burden of Premature Ventricular Complexes and Risk of Cardiomyopathy: A Cross-Sectional Study. JACC Clin Electrophysiol. 2025; S2405-500X(25)00014-3. doi: 10.1016/j.jacep.2025.01.004
  2. Kantharia B.K., Shah A.N. Are antiarrhythmic agents indicated in premature ventricular complex-induced cardiomyopathy and when? J Cardiovasc Electrophysiol. 2024; 35 (3): 574–82. doi: 10.1111/jce.16055
  3. Zafeiropoulos S., Doundoulakis I., Bekiaridou A. et al. Rhythm vs Rate Control Strategy for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2024; 10 (7 Pt 1): 1395–405. doi: 10.1016/j.jacep.2024.03.006
  4. Vetta G., Della Rocca D.G., Parlavecchio A. et al. Multielectrode catheter-based pulsed electric field vs. cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2024; 26 (12): euae293. doi: 10.1093/europace/euae293
  5. Saksena S., Ken-Opurum J., McKindley D.S. et al. Arrhythmia Recurrence and Rhythm Control Strategies After Catheter Ablation of Newly Diagnosed Atrial Fibrillation (ARRC-AF Study). JACC Clin Electrophysiol. 2025; S2405-500X(24)01027-2. doi: 10.1016/j.jacep.2024.11.020. Online ahead of print.
  6. Бокерия Л.А., Голухова Е.З., Попов С.В. и др. Российское кардиологическое общество. Наджелудочковые тахикардии у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (5): 4484 [Bokeria L. A., Golukhova E. Z., Popov S. V. et al. Russian Society of Cardiology. 2020 Clinical practice guidelines for Supraventricular tachycardia in adults. Russian Journal of Cardiology. 2021; 26 (5): 4484 (in Russ.)]. doi: 10.15829/1560-4071-2021-4484
  7. Frey W. Ueber vorhofflimern beim menschen und seine beseitigung durch chiniden. Berl Klin Wschr. 1918; 55: 417–9.
  8. Dan G.A., Martinez-Rubio A., Agewall S. et al.; ESC Scientific Document Group. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018; 20 (5): 731–732an. doi: 10.1093/europace/eux373
  9. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984; 24 (4): 129–47. doi: 10.1002/j.1552-4604.1984.tb01822.x
  10. Paolini E., Stronati G., Guerra F. et al. Flecainide: Electrophysiological properties, clinical indications, and practical aspects. Pharmacol Res. 2019; 148: 104443. doi: 10.1016/j.phrs.2019.104443
  11. Bryson H.M., Palmer K.J., Langtry H.D. et al. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs. 1993; 45 (1): 85–130. doi: 10.2165/00003495-199345010-00008
  12. Echt D.S., Liebson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324 (12): 781–8. doi: 10.1056/NEJM199103213241201
  13. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992; 327 (4): 227–33. doi: 10.1056/NEJM199207233270403
  14. Yang P.C., Giles W.R., Belardinelli L. et al. Mechanisms of flecainide induced negative inotropy: An in silico study. J Mol Cell Cardiol. 2021; 158: 26–37. doi: 10.1016/j.yjmcc.2021.05.007
  15. Канорский С.Г. Антиаритмическая терапия у больных с пароксизмальной и персистирующей формами фибрилляцией предсердий: определение достижимой цели и оценка имеющихся средств. Кардиология. 2014; 54 (2): 70–4 [Kanorskii S. G. Antiarrhythmic Therapy in Patients With Paroxysmal and Persistent Atrial Fibrillation: Identification of Achievable Goals and Assessment of Available Funds. Kardiologiia. 2014; 54 (2): 70–4 (in Russ.)].
  16. Арчакова О.А., Багаева Н.С., Комаров Т.Н. и др. Изучение фармакокинетики пролонгированного антиаритмического препарата лаппаконитина гидробромида (Аллафорте®, АО «Фармцентр ВИЛАР», Россия). Разработка и регистрация лекарственных средств. 2022; 11 (1): 140–7 [Archakova O. A., Bagaeva N. S., Komarov T. N. et al. Pharmacokinetics Study of the Long-acting Antiarrhythmic Drug of Lappaconitine Hydrobromide (Allaforte®, JSC "Pharmcenter VILAR", Russia). Drug development & registration. 2022; 11 (1): 140–7 (in Russ.)]. doi: 10.33380/2305-2066-2022-11-1-140-147
  17. Соколов С.Ф., Беляева М.М., Бакалов С.А. и др. Сравнительная эффективность и безопасность двух лекарственных форм лаппаконитина гидробромида при желудочковой экстрасистолии у больных без органической патологии сердца. Кардиология. 2017; 57 (4): 91–5 [Sokolov S.F., Belyaeva M.M., Bakalov S.A. et al. Comparative efficacy and safety of two medicine forms of lappaconitin hydrobromide in patients with ventricular extrasystole without organic pathology of the heart. Kardiologiia. 2017; 57 (4): 91–5 (in Russ.)]. doi: 10.18565/cardio.2017.4.5-11
  18. Tran Q.T., Baek I.H., Han N.Y. et al. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14 (7): 1446. doi: 10.3390/pharmaceutics14071446
  19. Кондори Леандро Э.И., Лебедев Д.С., Михайлов Е.Н. Терапевтические возможности флекаинида при нарушениях ритма сердца: краткий обзор исследований и клинических рекомендаций. Вестник аритмологии. 2024; 31 (3): е1-е7 [Condori Leandro H.I., Lebedev D.S., Mikhaylov E.N. Therapeutic potential of flecainide for cardiac arrhythmias: a short review of studies and clinical recommendations. Journal of Arrhythmology. 2024; 31 (3): е1-е7 (in Russ.)]. doi: 10.35336/VA-1397
  20. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (7): 4594 [Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021; 26 (7): 4594 (in Russ.)]. doi: 10.15829/1560-4071-2021-4594
  21. Van Gelder I.C., Rienstra M., Bunting K.V. et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45 (36): 3314–414. doi: 10.1093/eurheartj/ehae176
  22. Kojić D., Radunović A., Bukumirić Z. et al. Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol. Clin Cardiol. 2023; 46 (10): 1220–6. doi: 10.1002/clc.24090
  23. Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М. и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (7): 4600 [Lebedev D.S., Mikhailov E.N., Neminuschiy N.M. et al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021; 26 (7): 4600 (in Russ.)]. doi: 10.15829/1560-4071-2021-4600
  24. Ortmans S., Daval C., Aguilar M. et al. Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts. Expert Opin Pharmacother. 2019; 20 (17): 2101–14. doi: 10.1080/14656566.2019.1669561
  25. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43 (40): 3997–4126. doi: 10.1093/eurheartj/ehac262
  26. Соколов С.Ф., Бомонина Е.В. Сравнительная эффективность и безопасность аллапинина, этацизина и амиодарона и выбор оптимальной антиаритмической терапии по контролю ритма при пароксизмальной мерцательной аритмии. Кардиология: новости, мнения, обучение. 2015; 3: 65–75 [Sokolov S.F., Bomonina E.V. Comparative efficacy and safety of allapinine, ethacyzin and amiodarone: choice of optimal antiarrhythmic therapy for rhythm control in case of paroxysmal atrial fibrillation. Cardiology: news, opinions, training. 2015; 3: 65–75 (in Russ.)].
  27. Ревишвили А.Ш., Голицын С.П., Аксентьев С.Б. и др. Сравнительное исследование лаппаконитина гидробромида пролонгированного и пропафенона у пациентов с пароксизмальной фибрилляцией предсердий. Врач. 2024; 35 (1): 20–6 [Revishvili A., Golitsyn S., Aksentiev S. et al. A comparative study of lappaconitine hydrobromide extended release and propafenone in patients with paroxysmal atrial fibrillation. Vrach. 2024; 35 (1): 20–6 (in Russ.)]. doi: 10.29296/25877305-2024-01-04
  28. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9 (9): CD005049. doi: 10.1002/14651858.CD005049.pub5
  29. Миллер О.Н., Старичков С.А., Поздняков Ю.М. и др. Эффективность и безопасность применения пропафенона (пропанорма®) и амиодарона (кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка многоцентровое открытое рандомизированное проспективное сравнительное исследование ПРОСТОР. Российский кардиологический журнал. 2010; 4: 55–71 [Miller O.N., Starichkov S.A., Pozdnyakov Yu.M. et al. Effectiveness and safety of propafenone (propanorm®) and amiodarone (cordarone®) in patients with atrial fibrillation, arterial hypertension, coronary heart disease, and chronic heart failure with intact left ventricular systolic function. Russian Journal of Cardiology. 2010; 4: 55–71 (in Russ.)].
  30. Фомина И.Г., Тарзиманова А.И., Ветлужский А.В. и др. ПРОпафенон при восстановлении и сохранении синусового ритМа у больных с пЕрсисТирующЕй формой фибрилляции предсердиЙ. «ПРОМЕТЕЙ» – открытое мультицентровое исследование в РФ. Рациональная фармакотерапия в кардиологии. 2006; 2 (1): 37–40 [Fomina I.G., Tarzimanova A.I., Vetluzsky A.V. et al. PROpafenone for sinus rhythM recovery and support in patients with pErsisTEnt form of auricular fiblillation. "PROMETHEUS" – opened multicenter study in Russian Federation. Rational Pharmacother Card. 2006; 2 (1): 37–40 (in Russ.)].
  31. deSouza I.S., Shrestha P., Allen R. et al. Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis. Cardiovasc Drugs Ther. 2024. doi: 10.1007/s10557-024-07552-6
  32. Basza M., Maciejewski C., Bojanowicz W. et al. Flecainide in clinical practice. Cardiol J. 2023; 30 (3): 473–82. doi: 10.5603/CJ.a2023.0018
  33. Трешкур Т.В., Тулинцева Т.Э., Жабина Е.С. др. Оценка эффективности различных способов лечения желудочковой аритмии. Кардиологический вестник. 2019; 1: 46–53 [Treshkur T.V., Tulintseva T.E., Zhabina E.S. et al. Efficacy evaluation of various treatment options of ventricular arrhythmias. Cardiology Bulletin. 2019; 1: 46–53 (in Russ.)]. doi: 10.17116/Cardiobulletin20191401146
  34. Kuck K.H., Cappato R., Siebels J. et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102 (7): 748–54. doi: 10.1161/01.cir.102.7.748
  35. Burnham T.S., May H.T., Bair T.L. et al. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. Am Heart J. 2022; 243: 127–39. doi: 10.1016/j.ahj.2021.08.013
  36. Rillig A., Eckardt L., Borof K. et al. Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial. Europace. 2024; 26 (6): euae121. doi: 10.1093/europace/euae121
  37. Remme C.A. SCN5A channelopathy: arrhythmia, cardiomyopathy, epilepsy and beyond. Philos Trans R Soc Lond B Biol Sci. 2023; 378 (1879): 20220164. doi: 10.1098/rstb.2022.0164
  38. Akylbtkova E.L., Payne J.P., Newton C. et al. Gene-environment interaction between SCN5A-1103Y and hypokalemia influences QT interval prolongation in African Americans: the Jackson Heart Study. Am Heart J. 2014; 167 (1): 116–122.e1. doi: 10.1016/j.ahj.2013.10.009

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russkiy Vrach Publishing House